Autologous Cell Therapy Market (By Application: Cancer, Neuro-degenerative Disorder, Cardio-vascular Disorder; By End-use; By Source) - Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook and Forecast 2022-2030

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Autologous Cell Therapy Market 

5.1. COVID-19 Landscape: Autologous Cell Therapy Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Autologous Cell Therapy Market, By Source

8.1. Autologous Cell Therapy Market, by Source, 2022-2030

8.1.1 Bone Marrow

8.1.1.1. Market Revenue and Forecast (2017-2030)

8.1.2. Epidermis

8.1.2.1. Market Revenue and Forecast (2017-2030)

8.1.3. Mesenchymal stem cells

8.1.3.1. Market Revenue and Forecast (2017-2030)

8.1.4. Haematopoietic stem cells

8.1.4.1. Market Revenue and Forecast (2017-2030)

8.1.5. Chondrocytes

8.1.5.1. Market Revenue and Forecast (2017-2030)

8.1.6. Others

8.1.6.1. Market Revenue and Forecast (2017-2030)

Chapter 9. Global Autologous Cell Therapy Market, By Application

9.1. Autologous Cell Therapy Market, by Application, 2022-2030

9.1.1. Cancer

9.1.1.1. Market Revenue and Forecast (2017-2030)

9.1.2. Neurodegenerative disorders

9.1.2.1. Market Revenue and Forecast (2017-2030)

9.1.3. Cardiovascular disorders

9.1.3.1. Market Revenue and Forecast (2017-2030)

9.1.4. Autoimmune disorders

9.1.4.1. Market Revenue and Forecast (2017-2030)

9.1.5. Orthopaedics

9.1.5.1. Market Revenue and Forecast (2017-2030)

9.1.5. Wound healing

9.1.5.1. Market Revenue and Forecast (2017-2030)

9.1.5. Others

9.1.5.1. Market Revenue and Forecast (2017-2030)

Chapter 10. Global Autologous Cell Therapy Market, By End-Use 

10.1. Autologous Cell Therapy Market, by End-Use, 2022-2030

10.1.1. Hospitals & Clinics

10.1.1.1. Market Revenue and Forecast (2017-2030)

10.1.2. Academics & Research

10.1.2.1. Market Revenue and Forecast (2017-2030)

10.1.3. Others

10.1.3.1. Market Revenue and Forecast (2017-2030)

Chapter 11. Global Autologous Cell Therapy Market, Regional Estimates and Trend Forecast

11.1. North America

11.1.1. Market Revenue and Forecast, by Source (2017-2030)

11.1.2. Market Revenue and Forecast, by Application (2017-2030)

11.1.3. Market Revenue and Forecast, by End-Use (2017-2030)

11.1.4. U.S.

11.1.4.1. Market Revenue and Forecast, by Source (2017-2030)

11.1.4.2. Market Revenue and Forecast, by Application (2017-2030)

11.1.4.3. Market Revenue and Forecast, by End-Use (2017-2030)

11.1.5. Rest of North America

11.1.5.1. Market Revenue and Forecast, by Source (2017-2030)

11.1.5.2. Market Revenue and Forecast, by Application (2017-2030)

11.1.5.3. Market Revenue and Forecast, by End-Use (2017-2030)

11.2. Europe

11.2.1. Market Revenue and Forecast, by Source (2017-2030)

11.2.2. Market Revenue and Forecast, by Application (2017-2030)

11.2.3. Market Revenue and Forecast, by End-Use (2017-2030)

11.2.4. UK

11.2.4.1. Market Revenue and Forecast, by Source (2017-2030)

11.2.4.2. Market Revenue and Forecast, by Application (2017-2030)

11.2.4.3. Market Revenue and Forecast, by End-Use (2017-2030)

11.2.5. Germany

11.2.5.1. Market Revenue and Forecast, by Source (2017-2030)

11.2.5.2. Market Revenue and Forecast, by Application (2017-2030)

11.2.5.3. Market Revenue and Forecast, by End-Use (2017-2030)

11.2.6. France

11.2.6.1. Market Revenue and Forecast, by Source (2017-2030)

11.2.6.2. Market Revenue and Forecast, by Application (2017-2030)

11.2.6.3. Market Revenue and Forecast, by End-Use (2017-2030)

11.2.7. Rest of Europe

11.2.7.1. Market Revenue and Forecast, by Source (2017-2030)

11.2.7.2. Market Revenue and Forecast, by Application (2017-2030)

11.2.7.3. Market Revenue and Forecast, by End-Use (2017-2030)

11.3. APAC

11.3.1. Market Revenue and Forecast, by Source (2017-2030)

11.3.2. Market Revenue and Forecast, by Application (2017-2030)

11.3.3. Market Revenue and Forecast, by End-Use (2017-2030)

11.3.4. India

11.3.4.1. Market Revenue and Forecast, by Source (2017-2030)

11.3.4.2. Market Revenue and Forecast, by Application (2017-2030)

11.3.4.3. Market Revenue and Forecast, by End-Use (2017-2030)

11.3.5. China

11.3.5.1. Market Revenue and Forecast, by Source (2017-2030)

11.3.5.2. Market Revenue and Forecast, by Application (2017-2030)

11.3.5.3. Market Revenue and Forecast, by End-Use (2017-2030)

11.3.6. Japan

11.3.6.1. Market Revenue and Forecast, by Source (2017-2030)

11.3.6.2. Market Revenue and Forecast, by Application (2017-2030)

11.3.6.3. Market Revenue and Forecast, by End-Use (2017-2030)

11.3.7. Rest of APAC

11.3.7.1. Market Revenue and Forecast, by Source (2017-2030)

11.3.7.2. Market Revenue and Forecast, by Application (2017-2030)

11.3.7.3. Market Revenue and Forecast, by End-Use (2017-2030)

11.4. MEA

11.4.1. Market Revenue and Forecast, by Source (2017-2030)

11.4.2. Market Revenue and Forecast, by Application (2017-2030)

11.4.3. Market Revenue and Forecast, by End-Use (2017-2030)

11.4.4. GCC

11.4.4.1. Market Revenue and Forecast, by Source (2017-2030)

11.4.4.2. Market Revenue and Forecast, by Application (2017-2030)

11.4.4.3. Market Revenue and Forecast, by End-Use (2017-2030)

11.4.5. North Africa

11.4.5.1. Market Revenue and Forecast, by Source (2017-2030)

11.4.5.2. Market Revenue and Forecast, by Application (2017-2030)

11.4.5.3. Market Revenue and Forecast, by End-Use (2017-2030)

11.4.6. South Africa

11.4.6.1. Market Revenue and Forecast, by Source (2017-2030)

11.4.6.2. Market Revenue and Forecast, by Application (2017-2030)

11.4.6.3. Market Revenue and Forecast, by End-Use (2017-2030)

11.4.7. Rest of MEA

11.4.7.1. Market Revenue and Forecast, by Source (2017-2030)

11.4.7.2. Market Revenue and Forecast, by Application (2017-2030)

11.4.7.3. Market Revenue and Forecast, by End-Use (2017-2030)

11.5. Latin America

11.5.1. Market Revenue and Forecast, by Source (2017-2030)

11.5.2. Market Revenue and Forecast, by Application (2017-2030)

11.5.3. Market Revenue and Forecast, by End-Use (2017-2030)

11.5.4. Brazil

11.5.4.1. Market Revenue and Forecast, by Source (2017-2030)

11.5.4.2. Market Revenue and Forecast, by Application (2017-2030)

11.5.4.3. Market Revenue and Forecast, by End-Use (2017-2030)

11.5.5. Rest of LATAM

11.5.5.1. Market Revenue and Forecast, by Source (2017-2030)

11.5.5.2. Market Revenue and Forecast, by Application (2017-2030)

11.5.5.3. Market Revenue and Forecast, by End-Use (2017-2030)

Chapter 12. Company Profiles

12.1. BrainStorm Cell Therapeutics

12.1.1. Company Overview

12.1.2. Product Offerings

12.1.3. Financial Performance

12.1.4. Recent Initiatives

12.2. Holostem Terapie Avanzate S.R.L

12.2.1. Company Overview

12.2.2. Product Offerings

12.2.3. Financial Performance

12.2.4. Recent Initiatives

12.3. Lineage Cell Therapeutics Inc.

12.3.1. Company Overview

12.3.2. Product Offerings

12.3.3. Financial Performance

12.3.4. Recent Initiatives

12.4. Pharmicell Co. Inc

12.4.1. Company Overview

12.4.2. Product Offerings

12.4.3. Financial Performance

12.4.4. Recent Initiatives

12.5. Opexa Therapeutics

12.5.1. Company Overview

12.5.2. Product Offerings

12.5.3. Financial Performance

12.5.4. Recent Initiatives

12.6. Caladrius Biosciences Inc

12.6.1. Company Overview

12.6.2. Product Offerings

12.6.3. Financial Performance

12.6.4. Recent Initiatives

12.7. Castle Creek Biosciences Inc

12.7.1. Company Overview

12.7.2. Product Offerings

12.7.3. Financial Performance

12.7.4. Recent Initiatives

12.8. Regeneus Ltd.

12.8.1. Company Overview

12.8.2. Product Offerings

12.8.3. Financial Performance

12.8.4. Recent Initiatives

12.9. Opexa Therapeutics Inc

12.9.1. Company Overview

12.9.2. Product Offerings

12.9.3. Financial Performance

12.9.4. Recent Initiatives

12.10. Takeda Pharmaceutical Company Limited

12.10.1. Company Overview

12.10.2. Product Offerings

12.10.3. Financial Performance

12.10.4. Recent Initiatives

Chapter 13. Research Methodology

13.1. Primary Research

13.2. Secondary Research

13.3. Assumptions

Chapter 14. Appendix

14.1. About Us

14.2. Glossary of Terms